The Federal Circuit affirmed the decision of a federal district court in Illinois that Nexus Pharmaceuticals Inc. infringed Melinta Therapeutics LLC, Melinta Subsidiary Corp., and Rempex Pharmaceuticals Inc.'s patents for methods of adding magnesium to injectable antibiotic formulations to reduce hemolysis. The appeals court rejected Nexus’s challenges to claim construction and written description adequacy.
This summary was produced by Bloomberg Law Automation and edited by Bloomberg Law staff.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.